https://ku-0063794inhibitor.co....m/anatomical-as-well
The MTD of ralimetinib had been 100mg/12h with chemoradiotherapy. The three clients treated at 200mg/12h provided a dose-limiting toxicity one patient had a level 3 face edema, as well as 2 clients had a grade 3 rash and class 3 hepatic cytolysis (66%). Associated with the 18 enrolled patients, 15 received the MTD of ralimetinib. In the MTD, the grade≥3 unpleasant activities during concomitant chemoradiotherapy were hepatic cytolysis (2/15 clients), dermatitis/rash (1/15), lymphopenia (1
Like
Comment
Share
